Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recurrence × Fulvestrant × Clear all

Phase

Phase 2 3 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 56 Neoplasm Metastasis 10 Neoplasms 4 Advanced Breast Cancer 4 Multiple Endocrine Neoplasia Type 1 2 Hereditary Sensory and Autonomic Neuropathies 2 Recurrence 1 Neoplasms by Site 1 HR-positive, HER2-negative Breast Neoplasms 1 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1 Disease Progression 1 Carcinoma, Lobular 1 Carcinoma, Ductal, Breast 1 Breast Diseases 1

Interventions

Dexamethasone 23 Rituximab 15 Gemcitabine 11 Cisplatin 11 pomalidomide 10 Paclitaxel 10 Lenalidomide 9 Bortezomib 9 Carboplatin 8 Cyclophosphamide 7 carfilzomib 6 Drug Therapy 5 Cytarabine 5 selinexor 4 ibrutinib 4 daratumumab 4 Temozolomide 4 Doxorubicin 4 Docetaxel 4 Bevacizumab 4 Aspirin 4 tisagenlecleucel 3 Vincristine 3 Prednisone 3 Cetuximab 3 Calcium Dobesilate 3 ofatumumab 2 galiximab 2 eculizumab 2 durvalumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00256698 2012-08-01

FACT

AstraZeneca

Phase 3 Completed

514 enrolled 13 charts

Breast Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡